NCT06663306

Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

Efficacy and Safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 19 (estimated)
• Sponsor: Shanghai Chest Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.

Conditions

• Lung Cancer (NSCLC)
• Leptomeningeal Metastasis

Interventions

Type	Name	Description
DRUG	Pemetrexed	Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks
DRUG	Bevacizumab	Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.

Timeline

• Start date: 2024-12-09
• Primary completion: 2027-12-30
• Completion: 2027-12-30
• First posted: 2024-10-29
• Last updated: 2026-03-02

Locations

1 site across 1 country: China